



First International “Michele Baccarani” Conference on CML and related diseases



February 10th-11th, 2023
Starhotels Majestic, Turin

Honorary President: Giuseppe Saglio

Organizers: Daniela Cilloni, Giovanni Martinelli, Gianantonio Rosti

Scientific Committee: Massimo Breccia, Fausto Castagnetti, Claudio Cerchione, Daniela Cilloni, Carmen Fava, Robin Foà, Roberto Lemoli, Alessandro Lucchesi, Gerardo Musuraca, Cristina Papayannidis, Fabrizio Pane, Gianantonio Rosti, Domenico Russo, Giuseppe Saglio, Giorgina Specchia.

ECM accredited event: N. 2773-368974

14 ECM credits for n.100 participants Physicians, Nurses,
Biologists, TSLBs, Pharmacists



info@proeventi.it | www.proeventi.it

The Conference has been accredited to the Italian Ministry of Health:

Event n. 2773 - 368974

Provider n. 2773

14 ECM credits for n. 100 participants Physicians, Nurses,
Biologists, TSLBs, Pharmacists

Each participant, to obtain ECM credits, must participate in at least 90% of the scientific work and complete the online ECM questionnaire with a total of 75% of correct answers.

Attendance will be registered via barcode reader.

“Michele Baccarani” Conference on CML and related diseases

PATRONAGE



ASSOCIAZIONE ITALIANA
CONTRO LEUCEMIE
LINFOMI E MIELOMA

SIE
Società Italiana
di Ematologia



UNIVERSITÀ
DI TORINO

SUMMARY



6 SCIENTIFIC RATIONALE

8 MICHELE BACCARANI

11 SCIENTIFIC COMMITTEE

12 FRIDAY, FEBRUARY 10TH


16 SATURDAY, FEBRUARY 11TH

19 SUPPORTED BY

SCIENTIFIC

RATIONALE

The treatment of patients with chronic myeloid leukemia (CML) highlights an evolving story. Having reached the goal of survival almost equal to that of a control population without leukemia, problems remain regarding the treatment of a small proportion of patients still resistant to therapy with currently available BCR-ABL inhibitors (TKIs) and therefore still at risk of dying from disease-related causes, long-term toxicity problems due to continuous TKI intake, the need to increase the percentage of patients who can maintain a continuous remission even in the absence of TKI therapy (TFR), and the quality of life of patients. The meeting, dedicated to the most influential and distinguished Italian hematologist of the past decades in the field of CML, Prof. Michele Bacarani, one year after his passing, is aimed at establishing an exchange of views and experiences between CML physicians in Italy and leading European KOLs to focus on the most important points and projects to be explored in the near future regarding CML.



MICHELE BACCARANI

BIOGRAPHY



PROF. MICHELE BACCARANI (1942 - 2021)

Born in Bologna, 08/16/1942. Graduated in Medicine and Surgery, University of Bologna, 1966. Specialization in Blood Diseases, University of Modena, 1969. Research fellow, University of Bologna 1968-1970, University of Copenhagen, 1971. Assistant and assistant professor at the "L. and A. Seràgnoli" Institute of Hematology, University of Bologna, 1972-1985. Professor of Hematology, University of Trieste, 1986. Full Professor of Hematology and Director, Hematology Clinic, University of Udine, 1987 to 2000. Founder and Coordinator of the Department for Bone Marrow Transplantation, Udine from 1995 to 2000. Coordinator of the Coop. Italiano per lo Studio della Leucemia Mieloide Cronica (now CML Working Party of GIMEMA) since 1989. Vice dean of the Faculty of Medicine of the University of Bologna from 2001 to 2007. Full Professor of Haematology, University of Bologna and Director of the Institute of Haematology "L. e A. Seràgnoli", Integrated Care Department of Haematology, Oncology and Laboratory Medicine, Policlinico S.Orsola-Malpighi, Azienda Ospedaliero-Universitaria di Bologna, since 1.11.2000. Director of the Complex Unit of the Institutes of Cardiology and Hematology from November 1, 2004 to January 31, 2008. Director of the University Department of Hematology and Oncological Sciences "L. and A. Seràgnoli". Coordinator of the Center for the Study of Stem Cells at Policlinico S. Orsola-Malpighi, Bologna Hospitals, since May 2004. President of the Italian Society of Experimental Hematology 1995-1996. President of the Italian Society of Hematology 2002-2003. Main areas of research and clinical activity: acute leukemias, chronic myeloid leukemia, malignant lymphomas, cell kinetics, cancer chemotherapy, antiblastic drug resistance mechanisms, allogeneic and autologous bone marrow transplantation.

HONORARY

PRESIDENT

Giuseppe Saglio

ORGANIZERS



Daniela Cilloni

Giovanni Martinelli

Gianantonio Rosti

SCIENTIFIC

COMMITTEE

Massimo Breccia	Rome
Fausto Castagnetti	Bologna
Claudio Cerchione	Meldola (FC)
Daniela Cilloni	Turin
Carmen Fava	Turin
Robin Foà	Rome
Roberto Lemoli	Genoa
Alessandro Lucchesi	Meldola (FC)
Gerardo Musuraca	Meldola (FC)
Fabrizio Pane	Naples
Cristina Papayannidis	Bologna
Gianantonio Rosti	Meldola (FC)
Domenico Russo	Brescia
Giuseppe Saglio	Turin
Giorgina Specchia	Bari

13.30 PRESENTATION OF THE MEETING

Giovanni Martinelli, Fabrizio Pane

13.40 Inaugural Lecture:

Chairman: Claudio Cerchione

How we treat CML patients at MdAnderson in 2023

Hagop Kantarjian

14.00 THE CML CAMPUS PROJECT: OBSERVATIONAL STUDIES ON CML CLINICAL PRACTICE IN ITALY

Chairmen and introduction: Massimo Breccia, Giorgina Specchia

14.00 Observational study on the CML treatment in Italy

Giorgina Specchia

14.15 First-line CML treatment in Italy

Patrizia Pregno

14.30 Switching TKI therapy: when and how in clinical practice in Italy

Giovanna Rege-Cambrin

14.45 Pregnancy and CML in the Italian experience

Elisabetta Abruzzese

15.00 Dosages of TKIs in real life clinical practice

Alessandra Iurlo

15.15 Vascular TKI toxicity

Giovanni Caocci

15.30 CML Third-line treatment in Italy

Fabio Stagno

15.45 CML in the elderly

Roberto Latagliata

16.00 Allograft in CML: when and how

Antonella Gozzini

16.15 Second neoplasias in TKI treated CML patients: an emerging problem?
Federica Sorà

16.30 Coffee Break

16.50 Lecture:

Chairman: Giuseppe Saglio
The transition from interferon to TKI therapy
Carlo Gambacorti Passerini

17.10 GIMEMA CLINICAL TRIALS AND OTHER INVESTIGATOR INITIATED CLINICAL TRIALS IN ITALY

Chairmen: Fausto Castagnetti, Fabrizio Pane

17.10 The commitment of the GIMEMA WP on MPNs for clinical research in CML
Fabrizio Pane

17.25 Sustrenim Study
Fabrizio Pane

17.40 The Best trial
Fausto Castagnetti

17.55 Dante study
Gabriele Gugliotta

18.10 Asciminib, real life experience in Italy
Massimo Breccia

18.25 TKIs and interferons, where are we going?
Luigia Luciano

18.40 LEUKEMIC STEM CELLS***SESSION DEDICATED TO TESSA HOLYOAKE***

Chairman and introduction: Giovanni Martinelli

18.40 Hematopoietic Stem Cell Diseases

Alessandro Lucchesi

18.55 Specific and not specific Phenotypic markers as potential targets to hit LSCs

Monica Bocchia

19.10 Metabolic vulnerability of LSCs

Valentina Gaidano

19.25 Lecture:

Chairman: Claudio Cerchione

Systemic Mastocytosis, a no more neglected disease

Daniela Cilloni

19.40 End of Day 1

08.00 ROLE OF THE MOLECULAR BIOLOGY LAB IN THE TREATMENT OF CML

Chairmen: Francesco Di Raimondo, Roberto Lemoli

08.00 The LabNet model

Enrico Gottardi, Barbara Izzo

08.15 Importance of the early detection of the T315I and of the compound mutations for the right choice in the selection of the second line therapy

Simona Soverini

08.30 ddPCR in CML, will this become routine?

Sara Galimberti

08.45 TFR: THE ITALIAN AND EUROPEAN EXPERIENCE

Chairmen: Rudiger Hehlmann, Domenico Russo

08.45 The pioneer French experience

Francois-Xavier Mahon

09.00 Euroski, the latest update

Susan Saussele

09.30 Real life observational studies

Carmen Fava

09.45 2nd generation TKIs and TFR

Mario Tiribelli

10.00 In TKIs discontinuation are we following the correct scheme?

Massimiliano Bonifacio

10.15 Coffee Break

10.30 "MICHELE BACCARANI LECTURES"

Chairmen: Gerardo Musuraca, Gianantonio Rosti

10.30 Tribute to my professor Michele Bacarani
Gianantonio Rosti

10.50 The impact of ACA arising in the course of CML
Rudiger Hehlmann

11.10 Allogeneic transplant in CML: when and how
Jane Apperley

11.30 Generic TKIs: will they change our approach to CML therapy
Tomash Sacha

11.50 Are we using the correct sequence in TKI therapy?
Frank Nicolini

12.10 Lessons derived from CML in the management of MPNs
Tariq Mughal

12.30 Clinical and Biological lessons learned from CML
Robert Peter Gale

12.50 THE CML ADVOCATES ASSOCIATIONS

Chairman and introduction: Felice Bombaci

12.55 The importance of the quality of life for CML patients
Fabio Efficace

13.15 Lunch Time

14.00 PH-POSITIVE ALLS

Chairmen: Robin Foà, Giovanni Martinelli

14.00 How the chemo-free story in Ph+ ALL started and the role played by Michele Baccarani

Robin Foà

14.20 Ph-positive ALLs: Another curable leukemia without chemotherapy?

Giovanni Martinelli

14.40 The D-Alba protocol: after 4 years follow up

Sabrina Chiaretti

15.00 How I treat Ph-positive ALLs at MDAnderson in 2023

Elias Jabbour

15.20 Moab and bispecific in the Ph+ R/R ALL: the Neverending History

Cristina Papayannidis

15.50 Take home messages and end of the meeting

Giuseppe Saglio

SUPPORTED BY

AN UNRESTRICTED EDUCATIONAL GRANT FROM



Graphic Designer: **Mario Titone**

Turin | February 10th-11th, 2023

